Safety
hyperlipidemia, liver damage, dizziness, headache, hand‐foot syndrome, albuminuria
ADVERSE EVENT, LIVER DAMAGE, COMPLICATIONS, HYPERLIPIDEMIA
By October 15, 2021, the 16 patients treated with the combination therapy ranged from 6.2 to 31.7 months, and the combination therapy was well tolerated. The major complications were hyperlipidemia in 10 patients (62.5%), dizziness in nine (56.3%), liver damage in seven (43.75%), and headache in six (37.5%), and all these complications were grade 1 or 2 AEs. Only three (18.75%) patients occurred grade 3 apatinib‐related AEs which were hand‐foot syndrome or albuminuria, and two patients suspended combination therapy due to AEs for 1 week, and then continued but had a dosage reduction (Table Adverse events of 16 patients receiving combination therapy of ATRA and apatinib.Grade 2.Grade 3; others AE is grade 1.A total of 12 (75%) patients reduced their dosage of apatinib for AEs. Among them, five patients reduced the dosage of apatinib after suspending the medication, four (25%) patients reduced their dosage of ATRA, and one patient discontinued ATRA after 8 cycles for AE (Table 